Literature DB >> 29126817

Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients.

Yipeng Liu1, Xuan Li2, Chaoqun Ma3, Ping Wang2, Ju Liu4, Hong Su2, Hao Zhuo2, Xianglei Kong2, Dayu Xu5, Dongmei Xu6.   

Abstract

BACKGROUND: The M-type phospholipase A2 receptor (PLA2R) is a specific target autoantigen identified in idiopathic membranous nephropathy (IMN). The autoantibody against PLA2R (anti-PLA2R) may be used to diagnose IMN. However, the appropriate diagnosis cut-off value for Chinese patients with IMN has not been established.
METHODS: In total, 119 patients who underwent renal biopsy (57 patients with IMN and 62 patients with non-IMN glomerulonephritis) and 22 healthy individuals were recruited for our observation study from Qianfoshan Hospital between September 2011 and March 2016. The serum concentration of anti-PLA2R was measured using a quantitative enzyme-linked immunosorbent assay (ELISA). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and receiver operating characteristic (ROC) curve of anti-PLA2R in diagnosing IMN were analysed based on the ELISA detection.
RESULTS: The sensitivity, specificity, PPV, and NPV of anti-PLA2R in the diagnosis of IMN in the Chinese patients were 82.5, 75, 69.1, and 86.3% for the 2RU/ml cut-off value; 78.9, 91.7, 86.5, and 86.5% for the 2.6RU/ml cut-off value; 59.6, 95.2, 89.5, and 77.7% for the 14RU/ml cut-off value; 50.9, 96.4, 90.6, and 74.3% for the 20RU/ml cut-off value; and 47.4, 97.6, 93.1, and 73.2% for the 40RU/ml cut-off value, respectively. The area under the ROC curve was 0.879.
CONCLUSIONS: The cut-off value of 2.6RU/ml is recommended for the use of anti-PLA2R for the diagnosis of IMN in Chinese patients based on the ELISA.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Anti-PLA2R antibody; Cut-off value; ELISA; Idiopathic membranous nephropathy

Mesh:

Substances:

Year:  2017        PMID: 29126817     DOI: 10.1016/j.cca.2017.11.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

1.  High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

Authors:  Barbara Seitz-Polski; Karine Dahan; Hanna Debiec; Alexandra Rousseau; Marine Andreani; Christelle Zaghrini; Michel Ticchioni; Alessandra Rosenthal; Sylvia Benzaken; Ghislaine Bernard; Gérard Lambeau; Pierre Ronco; Vincent L M Esnault
Journal:  Clin J Am Soc Nephrol       Date:  2019-07-24       Impact factor: 8.237

Review 2.  The Role of Anti-PLA2R and Anti-THSD7A Antibodies in the Pathogenesis and Diagnostics of Primary Membranous Nephropathy: A Review of Current Knowledge for Clinical Practice.

Authors:  Iwona Smarz-Widelska; Dariusz Chojęta; Małgorzata M Kozioł
Journal:  Int J Environ Res Public Health       Date:  2022-04-27       Impact factor: 4.614

3.  Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy.

Authors:  Marilina Tampoia; Francesca Migliucci; Chiara Villani; Letizia Abbracciavento; Michele Rossini; Ruggiero Fumarulo; Loreto Gesualdo; Vincenzo Montinaro
Journal:  J Nephrol       Date:  2018-09-05       Impact factor: 3.902

Review 4.  Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era.

Authors:  Luisa Safar-Boueri; Albina Piya; Laurence H Beck; Rivka Ayalon
Journal:  Pediatr Nephrol       Date:  2019-12-06       Impact factor: 3.714

Review 5.  Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management.

Authors:  Sadiq Mu'azu Maifata; Rafidah Hod; Fadhlina Zakaria; Fauzah Abd Ghani
Journal:  Biomedicines       Date:  2019-11-01

6.  A New Chemiluminescence Immunoassay for Phospholipase A2 Receptor 1 Autoantibodies Allows Early Identification of Autoantibody Recurrence in Patients With Membranous Nephropathy.

Authors:  Elion Hoxha; Rolf A K Stahl; Linda Reinhard; Alexander Kühnl; Wolfgang Schlumberger; Cornelia Dähnrich
Journal:  Kidney Int Rep       Date:  2021-01-13

7.  Rapid, quantitative, and high-sensitivity detection of anti-phospholipase A2 receptor antibodies using a novel CdSe/ZnS-based fluorescence immunosorbent assay.

Authors:  Chenxi Li; Manyun Qian; Qiaozhen Hong; Xiaohong Xin; Zichun Sun; Yafeng Li; Bo Tang; Bing Gu
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

8.  Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis.

Authors:  Weiying Li; Yuliang Zhao; Ping Fu
Journal:  Front Med (Lausanne)       Date:  2018-04-26

9.  Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.

Authors:  Cornelia Dähnrich; Sandra Saschenbrecker; Iva Gunnarsson; Wolfgang Schlumberger; Pierre Ronco; Hanna Debiec
Journal:  Kidney Int Rep       Date:  2019-11-22

10.  Receptor antibody time-resolved A2 phospholipase bead immunochromatography and its application in idiopathic membranous nephropathy.

Authors:  Biao Huang; Xue Yang; Wenchen Zhang; Jian Wu; Pengfei Liu; Zhigang Hu; Tingting Wang
Journal:  J Clin Lab Anal       Date:  2020-08-06       Impact factor: 3.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.